Marex Group’s Ginkgo Bioworks DNA Stock Holding History

Marex Group’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,208	Closed	-$149K	–	654
2024 Q1	$149K	Buy	+3,208	New	+$166K	﹤0.01%	407
2023 Q4	–	Sell	-2,044	Closed	-$148K	–	573
2023 Q3	$148K	Sell	2,044 -1,841	-47%	-$147K	0.02%	199
2023 Q2	$289K	Sell	3,885 -11,540	-75%	-$683K	0.05%	175
2023 Q1	$821K	Buy	+15,425	New	+$977K	0.11%	126

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Marex Group's DNA Position: Q2 2024 in Review

Marex Group sold out of Ginkgo Bioworks (DNA) in Q2 2024, closing a stake of 3,208 shares — an estimated $149K sold.

Marex Group first reported a position in DNA in Q1 2023 and held it in 4 quarters. The position peaked at $821K in Q1 2023. 313 funds tracked by Wall St. Rank hold DNA as of Q2 2024.

Marex Group reported no remaining Ginkgo Bioworks position as of Q2 2024 after selling out during the quarter.
Marex Group sold 3,208 Ginkgo Bioworks shares in Q2 2024, an estimated $149K.
Marex Group first reported a position in Ginkgo Bioworks in Q1 2023 and held it in 4 quarters.
Marex Group's Ginkgo Bioworks position peaked at $821K in Q1 2023.
313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2024.

Based on Marex Group's 13F filing for Q2 2024, filed 2 Apr 2026.